Study Type
Interventional - Drug
The objective of the SCHOLAR-2 study is to evaluate whether is it safe and effective to continue trastuzumab in patients with early stage HER2 positive breast cancer who develop mild, minimally symptomatic or asymptomatic systolic left ventricular dysfunction.
Primary outcome:
The primary efficacy outcome will be the likelihood of completing trastuzumab as planned at its initiation.
The primary safety outcome will be left ventricular ejection fraction.
Interventional - Drug
Randomized clinical trial phase 2
9
13
130
2021 - 2024
PHRI
Back To Top